164 related articles for article (PubMed ID: 2465485)
21. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA.
Chiang SY; Welch J; Rauscher FJ; Beerman TA
Biochemistry; 1994 Jun; 33(23):7033-40. PubMed ID: 7516181
[TBL] [Abstract][Full Text] [Related]
22. Influence of minor groove binders on the eukaryotic topoisomerase II cleavage reaction with 41 base pair model oligonucleotides.
Bell A; Kittler L; Löber G; Zimmer C
Invest New Drugs; 1996; 13(4):271-84. PubMed ID: 8824345
[TBL] [Abstract][Full Text] [Related]
23. Linked lexitropsins and the in vitro inhibition of HIV-1 reverse transcriptase RNA-directed DNA polymerization: a novel induced-fit of 3,5 m-pyridyl bisdistamycin to enzyme-associated template-primer.
Filipowsky ME; Kopka ML; Brazil-Zison M; Lown JW; Dickerson RE
Biochemistry; 1996 Dec; 35(48):15397-410. PubMed ID: 8952492
[TBL] [Abstract][Full Text] [Related]
24. DNA minor groove binders as potential antitumor and antimicrobial agents.
Baraldi PG; Bovero A; Fruttarolo F; Preti D; Tabrizi MA; Pavani MG; Romagnoli R
Med Res Rev; 2004 Jul; 24(4):475-528. PubMed ID: 15170593
[TBL] [Abstract][Full Text] [Related]
25. Assignment of DNA binding sites for 4',6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). A comparative footprinting study.
Portugal J; Waring MJ
Biochim Biophys Acta; 1988 Feb; 949(2):158-68. PubMed ID: 2449244
[TBL] [Abstract][Full Text] [Related]
26. [Inhibition by ellipticine derivatives of the reactions catalysed by the topoisomerases: preferential inhibition of topoisomerase II].
Douc-Rasy S; Multon E; Kayser A; Riou G
C R Seances Acad Sci III; 1983; 296(19):899-904. PubMed ID: 6311366
[TBL] [Abstract][Full Text] [Related]
27. Effects of DAPI on human leukocytes in vitro.
Rocchi A; Di Castro M; Prantera G
Cytogenet Cell Genet; 1979; 23(4):250-4. PubMed ID: 87292
[TBL] [Abstract][Full Text] [Related]
28. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity.
Riou JF; Grondard L; Naudin A; Bailly C
Biochem Pharmacol; 1995 Jul; 50(3):424-8. PubMed ID: 7646545
[TBL] [Abstract][Full Text] [Related]
29. Oligopyrrole carboxamides linked with a nucleobase as potential DNA minor groove binding ligands: synthesis, DNA binding and biological evaluation.
Keuser C; Pindur U
Pharmazie; 2006 Apr; 61(4):261-8. PubMed ID: 16649534
[TBL] [Abstract][Full Text] [Related]
30. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
31. Dynamics in the DNA recognition by DAPI: exploration of the various binding modes.
Banerjee D; Pal SK
J Phys Chem B; 2008 Jan; 112(3):1016-21. PubMed ID: 18171050
[TBL] [Abstract][Full Text] [Related]
32. Selective toxicity to malaria parasites by non-intercalating DNA-binding ligands.
Ginsburg H; Nissani E; Krugliak M; Williamson DH
Mol Biochem Parasitol; 1993 Mar; 58(1):7-15. PubMed ID: 7681547
[TBL] [Abstract][Full Text] [Related]
33. Effects of a hairpin polyamide on DNA melting: comparison with distamycin and Hoechst 33258.
James PL; Le Strat L; Ellervik U; Bratwall C; Nordén B; Brown T; Fox KR
Biophys Chem; 2004 Nov; 111(3):205-12. PubMed ID: 15501563
[TBL] [Abstract][Full Text] [Related]
34. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
Soderlind KJ; Gorodetsky B; Singh AK; Bachur NR; Miller GG; Lown JW
Anticancer Drug Des; 1999 Feb; 14(1):19-36. PubMed ID: 10363025
[TBL] [Abstract][Full Text] [Related]
35. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
36. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
37. Concerted DNA recognition and novel site-specific alkylation by duocarmycin A with distamycin A.
Yamamoto K; Sugiyama H; Kawanishi S
Biochemistry; 1993 Feb; 32(4):1059-66. PubMed ID: 8424935
[TBL] [Abstract][Full Text] [Related]
38. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
39. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
[TBL] [Abstract][Full Text] [Related]
40. Distamycin A affects the stability of NF-kappaB p50-DNA complexes in a sequence-dependent manner.
Speight RE; Hart DJ; Blackburn JM
J Mol Recognit; 2002; 15(1):19-26. PubMed ID: 11870918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
